Latest news with #genomeediting
Yahoo
30-07-2025
- Business
- Yahoo
Japan Genome Editing Market Size, Share & Trends Analysis Report 2025-2033: Japan's Genome Editing Market Set to Reach USD 1.45 Billion by 2033
Japan's genome editing market, valued at USD 1.45 billion by 2033, grows at a 17.97% CAGR, driven by precision medicine and biotech investment. Key technologies like CRISPR/Cas9 lead, supported by regulatory policies and research infrastructure. The market is pivotal for gene therapies, agricultural biotech, and more. Japanese Genome Editing Market Dublin, July 30, 2025 (GLOBE NEWSWIRE) -- The "Japan Genome Editing Market Size, Share & Trends Analysis Report By Technology (CRISPR/Cas9), By Delivery Method (Ex Vivo), By Application (Genetic Engineering, Clinical Applications), By Mode (Contract, In-house), By End Use, And Segment Forecasts, 2025 - 2033" report has been added to Japanese genome editing market size is projected to reach USD 1.45 billion by 2033, growing at a CAGR of 17.97% from 2025 to 2033. Japan's genome editing market is witnessing robust expansion, propelled by increasing investment in precision medicine, regenerative therapies, and agricultural biotechnology. The growing focus on next-generation therapeutics, particularly gene therapies, rare disease treatments, and personalized oncology solutions, fuels demand for advanced genome editing technologies such as CRISPR-Cas9, TALENs, and base editors. Regulatory encouragement and supportive government initiatives, including funding for biotech innovation and streamlining of clinical approval processes, further accelerate market momentum. A strong academic and research infrastructure and the presence of globally recognized institutions underpin innovation and collaboration across sectors. Pharmaceutical companies, biotech startups, and educational consortia are increasingly converging to translate gene editing breakthroughs into viable clinical and commercial applications. Japan's aging population and rising incidence of chronic genetic disorders are also driving urgency around genome-targeted interventions, catalyzing demand for safe, effective, and scalable editing advancements in delivery systems, precision targeting, and off-target risk mitigation are expanding genome editing's therapeutic applicability. Integration with digital tools and AI-driven bioinformatics platforms is improving target discovery, optimizing design workflows, and accelerating preclinical development. In agriculture and food biotechnology, gene editing is applied to develop disease-resistant, high-yield crops, aligning with national food security and sustainability cross-sector partnerships, increased R&D activity, and supportive policy frameworks, the Japan genome editing market is well-positioned to play a leading role in shaping the future of precision biotechnology. Strategic alliances, localized manufacturing, and a growing IP portfolio reinforce Japan's position as a key hub for genome editing innovation in therapeutic and non-therapeutic Genome Editing Market Report Highlights By technology, CRISPR/Cas9 dominated the Japan genome editing market with a market share of 44.14% in 2024. This dominance stems from CRISPR/Cas9's superior efficiency, precision, and cost-effectiveness in targeted genome modifications. Its widespread adoption across research institutes, biotech startups, and pharmaceutical companies reflects its ability to accelerate functional genomics studies, therapeutic development, and agricultural innovation. The relatively easier design and scalability of CRISPR/Cas9 tools make them the preferred choice for both in vitro and in vivo applications. By delivery method, in vivo genome editing led the market with a market share of 50.63% in 2024, driven by rising investments in gene therapy and regenerative medicine, especially for treating inherited diseases and cancers. Japan's advanced healthcare infrastructure and focus on curative therapies have fueled the development of novel delivery platforms, such as lipid nanoparticles and adeno-associated viral vectors (AAVs), enabling more effective gene transfer in living organisms. The ability to directly edit genes within the patient offers transformative potential and continues to attract clinical trial activity and investment. By application, genetic engineering emerged as the leading segment, with a market share of 73.16% in 2024, contributing the highest revenue share. The segment's growth is driven by Japan's commitment to disease modeling, therapeutic discovery, and functional genomics research. Genetic engineering is widely used across academia and industry to develop customized cell lines, engineer model organisms, and advance gene therapy pipelines. It also plays a crucial role in precision breeding for agriculture and aquaculture, which are strategic sectors in Japan's biotech innovation agenda. By mode, the contract segment held the largest share of 66.77% in 2024, as outsourcing genome editing services becomes increasingly common among biotech startups and research institutions. Contract service providers offer specialized expertise, infrastructure, and regulatory support, allowing innovators to reduce time-to-market and control development costs. Japan's strong contract research and manufacturing organization ecosystem supports gene editing across preclinical, clinical, and commercial phases. By end use, biotechnology and pharmaceutical companies dominated the Japan genome editing market with a share of 49.66% in 2024. These companies leverage genome editing to accelerate drug discovery, develop gene and cell therapies, and explore novel treatment modalities for complex diseases. With robust R&D pipelines and increasing government incentives, these end users are at the forefront of innovation. Collaborations with academic institutions and global biotech firms further strengthen their position, making them central players in the commercial Application of genome editing technologies. In January 2025, Takara Bio USA Holdings, Inc. completed the acquisition of California-based Curio Bioscience, integrating its Trekker and Seeker spatial-biology platforms into its U.S. single-cell omics portfolio. Key Attributes: Report Attribute Details No. of Pages 110 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $323.1 Million Forecasted Market Value (USD) by 2033 $1450 Million Compound Annual Growth Rate 17.9% Regions Covered Japan Key Topics Covered: Chapter 1. Methodology and ScopeChapter 2. Executive Summary 2.1. Market Outlook2.2. Segment Snapshot2.3. Competitive Landscape SnapshotChapter 3. Market Variables, Trends, & Scope 3.1. Market Lineage Outlook3.2. Market Dynamics3.3. Japan Genome Editing Market Analysis ToolsChapter 4. Japan Genome Editing Market: Technology Business Analysis 4.1. Technology Segment Dashboard4.2. Japan Genome Editing Market Technology Movement Analysis4.3. Japan Genome Editing Market Size & Trend Analysis, by Technology4.4. CRISPR/Cas94.5. TALENs/MegaTALs4.6. ZFN4.7. Meganucleases4.8. OthersChapter 5. Japan Genome Editing Market: Delivery Method Business Analysis 5.1. Delivery Method Segment Dashboard5.2. Japan Genome Editing Market Delivery Method Movement Analysis5.3. Japan Genome Editing Market Size & Trend Analysis, by Delivery Method5.4. Ex-vivo5.5. In- vivoChapter 6. Japan Genome Editing Market: Application Business Analysis 6.1. Application Segment Dashboard6.2. Japan Genome Editing Market Application Movement Analysis6.3. Japan Genome Editing Market Size & Trend Analysis, by Application6.4. Genetic Engineering6.4.1. Genetic Engineering market estimates and forecasts 2021 to 20336.4.2. Cell line engineering6.4.3. Animal genetic engineering6.4.4. Plant genetic engineering6.4.5. Others6.5. Clinical Applications6.5.1. Clinical Applications market estimates and forecasts 2021 to 20336.5.2. Therapy Development6.5.3. Diagnostics DevelopmentChapter 7. Japan Genome Editing Market: Mode Business Analysis 7.1. Mode Segment Dashboard7.2. Japan Genome Editing Market Mode Movement Analysis7.3. Japan Genome Editing Market Size & Trend Analysis, by Mode7.4. Contract7.5. In- houseChapter 8. Japan Genome Editing Market: End Use Estimates & Trend Analysis 8.1. End Use Segment Dashboard8.2. Japan Genome Editing Market End Use Movement Analysis8.3. Japan Genome Editing Market Size & Trend Analysis, by End Use8.4. Biotechnology & Pharmaceutical Companies8.5. Academic & Research Institutes8.6. Contract Research OrganizationsChapter 9. Competitive Landscape 9.1. Company/Competition Categorization9.2. Strategy Mapping9.3. Company Market Position Analysis, 20249.4. Company Profiles Merck KGaA Takara Bio Inc. Revvity, Inc. Danaher Corporation GenScript New England Biolabs Lonza Thermo Fisher Scientific, Inc. Charles River Laboratories Eurofins Scientific For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Japanese Genome Editing Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Zawya
16-07-2025
- Science
- Zawya
Precision breeding powers climate resilience in South Africa
At the 2025 South African National Seed Organisation (SANSOR) Congress in Pretoria, Dr Geoff Graham, vice president of plant breeding at Corteva Agriscience, shared insights into the evolving role of precision breeding, genome editing, and digital technologies in developing climate-resilient crops tailored for South Africa's challenging agricultural environment. Source: Supplied He discussed how these innovations contribute to food security, sustainability, and adaptation to climate change. A century of maize breeding progress Plant breeding has evolved over nearly 100 years, transitioning from open-pollinated maize varieties to hybrids—a shift that substantially improved crop yields. In the United States, maize productivity increased sixfold over the past century, from under 2 tonnes per hectare to more than 11 tonnes per hectare. South Africa has seen similar progress, with maize yields rising from less than 1 tonne per hectare in the early 1900s to over 5 tonnes today. These gains are attributed to advances in plant breeding, biotechnology, irrigation, and improved farming practices, which have enhanced food security and rural livelihoods while increasing agricultural efficiency. Genome editing: A new frontier in plant breeding Developing traits like herbicide tolerance or pest resistance traditionally takes over a decade and requires substantial financial investment, including research and development, extensive safety assessments, and compliance with strict regulations. These barriers limit access for smaller seed companies and research institutions. Dr Graham explained: "In contrast, genome editing holds significant promise and could become more widely accessible to a range of industry stakeholders and seed companies if an appropriate regulatory framework is adopted." He added that genome editing can empower universities and public research organisations to innovate, offering farmers improved tools to boost productivity, reduce losses, and adapt to changing climates—ultimately supporting food security, lowering input costs, and strengthening rural economies. Digital technologies enhance breeding efficiency Corteva's breeding programmes now incorporate artificial intelligence (AI), predictive analytics, and digital phenotyping to accelerate early selection and reduce costs. This ensures that only the most promising genetic material advances through the breeding pipeline. Maize, a key South African crop, benefits from gene editing to develop multi-disease resistance against pathogens such as Northern Corn Leaf Blight and Grey Leaf Spot. While global technology integration advances, local product development and testing remain critical. Significant investment in local trial infrastructure helps ensure hybrids are optimised for specific regional conditions. Breeding for sustainability and climate resilience Efforts continue to develop crop varieties—including maize, sunflower, and soybeans—with traits like heat tolerance, disease resistance, and yield stability, which are essential under changing climate conditions. Dr Graham highlighted the importance of these advances, noting that they enable increased food production on the same or even less land area. Looking ahead, plant breeding will also play a role in sustainability goals such as renewable fuel production. Corteva's work on high-oilseed crops aligns with the growing demand for sustainable aviation fuel, impacting land use and carbon emissions. A vision rooted in legacy, driven by technology Dr Graham referenced early agricultural pioneers who believed in the transformative potential of modern breeding. He stated: "The combination of gene editing, digital innovation and local adaptation provides powerful tools for addressing the most pressing challenges in global agriculture—from disease management to food security and climate change." He concluded that the future of agriculture depends on the responsible adoption of cutting-edge technology, supported by thoughtful regulation and ongoing investment, to feed a growing global population and build a resilient, sustainable food system. All rights reserved. © 2022. Provided by SyndiGate Media Inc. (
